- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00415350
Bronchiectasis and Long Term Azithromycin Treatment (BAT)
Bronchiectasis and Long Term Azithromycin Treatment: A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment
1. SUMMARY
Rationale: Patients with bronchiectasis often experience lower respiratory tract infections with progression of symptoms and decline in quality of life. Macrolides, as has been shown in panbronchiolitis and cystic fibrosis, may break or weaken the link between infection and inflammation resulting in an improvement of symptoms. Also the number of exacerbations may lowered.
Objective: A reduction in number of infective exacerbations and improvement in lung function by AZT treatment are the primary objectives. Secondary objectives that will be evaluated are: symptoms score, quality of life, inflammatory parameters, bacterial colonisation, and adverse events.
Study design: Randomised double blind multicenter study in the Netherlands. Patients will be stratified for colonisation with P.aeruginosa.
Study population: Patients with bronchiectasis demonstrated by high-resolution computed tomography (HR-CT) scan or bronchography.
Intervention: Patients receive Azithromycin 250mg(p.o.) once daily or placebo.
Main study parameters/endpoints: Reduction in number exacerbations, defined as increase symptoms such as dyspnoea, coughing, and sputum production for which a course of prednisolone and/or antibiotic is needed. Change in lung function parameters (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC]) measured by spirometry is the other primary endpoint.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risk of participating in this study is low. Laboratory, radiographic examinations, and pulmonary function tests are commonly used as diagnostic procedures during outpatients visits and during exacerbations. Adverse effects in maintenance treatment with AZT are usually mild and mainly gastrointestinal. Sometimes rash and abnormal liver function tests are observed. A better quality of life will probably be the beneficial effect of long term treatment with AZT. This will be achieved by a reduction in respiratory and non-respiratory symptoms and number of exacerbations.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands
- AMC
-
Amsterdam, Netherlands
- st Lucas Andreas Ziekenhuis
-
Beverwijk, Netherlands
- Rode Kruis Ziekenhuis
-
Deventer, Netherlands
- Deventer Ziekenhuis
-
Groesbeek, Netherlands
- U.L.C. Dekkerswald
-
Groningen, Netherlands
- University Hospital Groningen (UMCG)
-
Heerlen, Netherlands
- Atrium medisch centrum
-
Hilversum, Netherlands
- Tergooi ziekenhuizen
-
Hoofddorp, Netherlands
- Spaarne Ziekenhuis
-
Leeuwarden, Netherlands
- MC Leeuwarden
-
Nieuwegein, Netherlands
- Antonius Ziekenhuis
-
Rotterdam, Netherlands
- Erasmus Medical Center
-
Utrecht, Netherlands
- Diakonessenhuis
-
Venlo, Netherlands
- VieCuri MC
-
Zwolle, Netherlands
- Isala Klinieken
-
-
N-H
-
Alkmaar, N-H, Netherlands, 1800AM
- Alkmaar Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18 ≥ years
- Bronchiectasis diagnosed by plain bronchography or high resolution computer tomography.
- Minimal 3 lower respiratory tract infections (LRTI) treated with oral/intravenous (IV) antibiotics in the year preceding the study inclusion.
- The presence of chronic respiratory symptoms such as cough, dyspnoea, expectoration of sputum.
- At least one positive sputum culture in the preceding year.
- Informed consent
Exclusion Criteria:
- Previous ( ≥ 4 weeks) prolonged macrolide therapy.
- Pregnant or lactating women.
- Allergy to macrolides.
- Intolerance to macrolides.
- Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more times the upper limit of normal).
- Use of antibiotics within 14 days of screening.
- Use of oral or IV corticosteroids (≥ 30 mg prednisolone/daily) within 30 days of screening.
- Other research medication started 2 months prior to inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo 2
|
Placebo tablet 1 daily
|
Active Comparator: Azithromycin treatment 1
|
Azithromycin Tablet 250 mg daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Does prolonged antibiotic treatment with AZM reduce the number of bacterial exacerbations in patients with bronchiectasis?
Time Frame: 1 year
|
1 year
|
Does treatment with AZM increase lung function parameters (Δ FEV1, Δ FVC )?
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Is there any improvement in symptom score during treatment with AZM?
Time Frame: 1 year
|
1 year
|
What is the effect of AZM on bacterial colonisation?
Time Frame: 1 year
|
1 year
|
Does treatment with AZM reduce inflammatory parameters?
Time Frame: 1 year
|
1 year
|
Does treatment with AZM change the quality of life?
Time Frame: 1 year
|
1 year
|
Is there any differences in adverse events between AZM and placebo treatment?
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: W.G. Boersma, MD,PHD, Medical Center Alkmaar, dep. Pulmomary Diseases
Publications and helpful links
General Publications
- Terpstra LC, Altenburg J, Mohamed Hoesein FA, Bronsveld I, Go S, van Rijn PAC, De Jong PA, Heijerman HGM, Boersma WG. The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial. Respir Med. 2022 Feb;192:106718. doi: 10.1016/j.rmed.2021.106718. Epub 2021 Dec 28.
- Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013 Mar 27;309(12):1251-9. doi: 10.1001/jama.2013.1937.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BAT-2006-MCA1
- BAT-2006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Singapore National Eye CentreCompletedIntraocular Inflammation in ChildrenSingapore
Clinical Trials on Azithromycin
-
Washington University School of MedicineCompletedRespiratory Syncytial Virus, BronchiolitisUnited States
-
PfizerCompletedTonsillitis | PharyngitisBelgium, India, Germany, United States, France, United Kingdom, Netherlands, Finland, Italy, Norway
-
Sheba Medical CenterUnknown
-
PfizerCompletedBacterial Infections
-
Thomas Jefferson UniversityChristiana Care Health ServicesCompletedPreterm Premature Rupture of MembraneUnited States
-
GlaxoSmithKlineCompletedAutoimmune DiseasesUnited Kingdom
-
Emory UniversityThe Carter CenterSuspended
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
University of Alabama at BirminghamCompletedRespiratory Syncytial VirusUnited States